Polymorphisms in the SNCA Gene: Association with the Risk of Development of the Sporadic Form of Parkinson’s Disease and the Level of SNCA Gene Expression in Peripheral Blood of Patients from Russia

Anelya Kh. Alieva, Maria I. Shadrina, Elena V. Filatova, Vera V. Ustinova, Ekaterina Yu Fedotova, Alexey V. Karabanov, Sergey N. Illarioshkin, Petr A. Slominsky

Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, Russia.
Research Centre of Neurology, Russian Academy of Medical Sciences, Moscow, Russi.
Research Centre of Neurology, Russian Academy of Medical Sciences, Moscow, Russia.

DOI: 10.4236/nm.2013.44032                

Abstract

Parkinson’s disease (PD) is one of the most common human neurodegenerative disorders caused by the loss of dopaminergic neurons in the brain. The α-synuclein (SNCA) gene is one of the most studied genes involved in the pathogenesis of PD. In our study, we conducted a genetic analysis of promoter and intron single-nucleotide polymorphisms (SNPs) in the SNCA gene. We also analyzed the association of genotypes of these SNPs with expression levels of SNCA mRNA. One of four SNPs in the SNCA gene, and the rs2736990 polymorphism, associates with the risk of the sporadic form of PD in Russian population. The risk of PD was increased almost twofold in carriers of allele C (odds ratios = 1.9, 95% confidence interval: 1.2-2.91, p = 0.003). However, no association was found between any of the genotypes of SNPs tested (rs2583988, rs2619363, rs2619364 and rs2736990) and alterations in SNCA levels. Our findings support the hypothesis that the rs2736990 polymorphism is associated with PD. SNPs rs2583988, rs2619363 and rs2619364 in the promoter region of the SNCA gene themselves do not significantly influence the expression of SNCA. Most likely, SNCA gene expression is a very complex process that is affected by different genetic and epigenetic factors.

Keywords

Parkinson’s Disease; Expression Analysis; SNCA; SNP

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson’s Disease,” The Lancet Neurology, Vol. 5, No. 6, 2006, pp. 525-535. http://dx.doi.org/10.1016/S1474-4422(06)70471-9
[2]	L. Yavich, H. Tanila, S. Vepsalainen and P. Jakala, “Role of Alpha-Synuclein in Presynaptic Dopamine Recruitment,” The Journal of Neuroscience, Vol. 24, No. 49, 2004, pp. 11165-11170.
[3]	J. Burre, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton and T. C. Sudhof, “Alpha-Synuclein Promotes Snare-Complex Assembly in Vivo and in Vitro,” Science, Vol. 329, No. 5999, 2010, pp. 1663-1667. http://dx.doi.org/10.1126/science.1195227
[4]	B. K. Choi, M. G. Choi, J. Y. Kim, Y. Yang, Y. Lai, D. H. Kweon, N. K. Lee and Y. K. Shin, “Large Alpha-Synuclein Oligomers Inhibit Neuronal Snare-Mediated Vesicle Docking,” Proceedings of the National Academy of Sciences of USA, Vol. 110, No. 10, 2013, pp. 4087-4092. http://dx.doi.org/10.1073/pnas.1218424110
[5]	J. J. McCarthy, C. Linnertz, L. Saucier, J. R. Burke, C. M. Hulette, K. A. Welsh-Bohmer and O. Chiba-Falek, “The Effect of SNCA 3’ Region on the Levels of SNCA-112 Splicing Variant,” Neurogenetics, Vol. 12, No. 1, 2011, pp. 59-64. http://dx.doi.org/10.1007/s10048-010-0263-4
[6]	M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe and R. L. Nussbaum, “Mutation in the Alpha-Synuclein Gene Identified in Families with Parkinson’s Disease,” Science, Vol. 276, No. 5321, 1997, pp. 2045-2047. http://dx.doi.org/10.1126/science.276.5321.2045
[7]	M. C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, S. Lincoln, C. Levecque, L. Larvor, J. Andrieux, M. Hulihan, N. Waucquier, L. Defebvre, P. Amouyel, M. Farrer and A. Destee, “Alpha-Synuclein Locus Duplication as a Cause of Familial Parkinson’s Disease,” Lancet, Vol. 364, No. 9440, 2004, pp. 1167-1169. http://dx.doi.org/10.1016/S0140-6736(04)17103-1
[8]	A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M. R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy and K. GwinnHardy, “Alpha-Synuclein Locus Triplication Causes Parkinson’s Disease,” Science, Vol. 302, No. 5646, 2003, pp. 841. http://dx.doi.org/10.1126/science.1090278
[9]	M. C. Chartier-Harlin, J. Kachergus, C. Roumier, et al., “Alpha-Synuclein Locus Duplication as a Cause of Familial Parkinson’s Disease,” Lancet, Vol. 364, No. 9440, 2004, pp. 1167-1169. http://dx.doi.org/10.1016/S0140-6736(04)17103-1
[10]	K. Nishioka, S. Hayashi, M. J. Farrer, et al., “Clinical Heterogeneity of Alpha-Synuclein Gene Duplication in Parkinson’s Disease,” Annals of Neurology, Vol. 59, No. 2, 2006, pp. 298-309.
[11]	T. Sekine, H. Kagaya, M. Funayama, Y. Li, H. Yoshino, H. Tomiyama and N. Hattori, “Clinical Course of the First Asian Family with Parkinsonism Related to SNCA Triplication,” Movement Disorders, Vol. 25, No. 16, 2010, pp. 2871-2875. http://dx.doi.org/10.1002/mds.23313
[12]	T. L. Edwards, W. K. Scott, C. Almonte, A. Burt, E. H. Powell, G. W. Beecham, L. Wang, S. Züchner, I. Konidari, G. Wang, C. Singer, F. Nahab, B. Scott, J. M. Stajich, M. Pericak-Vance, J. Haines, J. M. Vance and E. R. Martin, “Genome-Wide Association Study Confirms SNPs in SNCA and the Mapt Region as Common Risk Factors for Parkinson Disease,” Annals of Human Genetics, Vol. 74, No. 2, 2010, pp. 97-109. http://dx.doi.org/10.1111/j.1469-1809.2009.00560.x
[13]	J. Simon-Sanchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs, D. Berg, C. Paisan-Ruiz, P. Lichtner, S. W. Scholz, D. G. Hernandez, R. Kruger, M. Federoff, C. Klein, A. Goate, J. Perlmutter, M. Bonin, M. A. Nalls, T. Illig, C. Gieger, H. Houlden, M. Steffens, M. S. Okun, B. A. Racette, M. R. Cookson, K. D. Foote, H. H. Fernandez, B. J. Traynor, S. Schreiber, S. Arepalli, R. Zonozi, K. Gwinn, M. van der Brug, G. Lopez, S. J. Chanock, A. Schatzkin, Y. Park, A. Hollenbeck, J. Gao, X. Huang, N. W. Wood, D. Lorenz, G. Deuschl, H. Chen, O. Riess, J. A. Hardy, A. B. Singleton and T. Gasser, “Genome-Wide Association Study Reveals Genetic Risk Underlying Parkinson’s Disease,” Nature Genetics, Vol. 41, No. 12, 2009, pp. 1308-1312. http://dx.doi.org/10.1038/ng.487
[14]	E. K. Tan, T. Matsuura, S. Nagamitsu, M. Khajavi, J. Jankovic and T. Ashizawa, “Polymorphism of Nacp-Rep1 in Parkinson’s Disease: An Etiologic Link with Essential Tremor?” Neurology, Vol. 54, No. 5, 2000, pp. 1195-1198. http://dx.doi.org/10.1212/WNL.54.5.1195
[15]	Y. Xia, H. A. Rohan de Silva, B. L. Rosi, L. H. Yamaoka, J. B. Rimmler, M. A. Pericak-Vance, A. D. Roses, X. Chen, E. Masliah, R. DeTeresa, A. Iwai, M. Sundsmo, R. G. Thomas, C. R. Hofstetter, E. Gregory, L. A. Hansen, R. Katzman, L. J. Thal and T. Saitoh, “Genetic Studies in Alzheimer’s Disease with an Nacp/Alpha-Synuclein Polymorphism,” Annals of Neurology, Vol. 40, No. 2, 1996, pp. 207-215. http://dx.doi.org/10.1002/ana.410400212
[16]	O. Chiba-Falek, J. W. Touchman and R. L. Nussbaum, “Functional Analysis of Intra-Allelic Variation at Nacp-Rep1 in the Alpha-Synuclein Gene,” Human Genetics, Vol. 113, No. 5, 2003, pp. 426-431. http://dx.doi.org/10.1007/s00439-003-1002-9
[17]	K. D. Cronin, D. Ge, P. Manninger, C. Linnertz, A. Rossoshek, B. M. Orrison, D. J. Bernard, O. M. El-Agnaf, M. G. Schlossmacher, R. L. Nussbaum and O. Chiba-Falek, “Expansion of the Parkinson Disease-Associated SNCA-Rep1 Allele Upregulates Human Alpha-Synuclein in Transgenic Mouse Brain,” Human Molecular Genetics, Vol. 18, No. 17, 2009, pp. 3274-3285. http://dx.doi.org/10.1093/hmg/ddp265
[18]	C. Linnertz, L. Saucier, D. Ge, K. D. Cronin, J. R. Burke, J. N. Browndyke, C. M. Hulette, K. A. Welsh-Bohmer and O. Chiba-Falek, “Genetic Regulation of Alpha-Synuclein Mrna Expression in Various Human Brain Tissues,” PLoS ONE, Vol. 4, No. 10, 2009, p. e7480. http://dx.doi.org/10.1371/journal.pone.0007480
[19]	O. A. Ross, D. Gosal, J. T. Stone, S. J. Lincoln, M. G. Heckman, G. B. Irvine, J. A. Johnston, J. M. Gibson, M. J. Farrer and T. Lynch, “Familial Genes in Sporadic Disease: Common Variants of Alpha-Synuclein Gene Associate with Parkinson’s Disease,” Mechanisms of Ageing and Development, Vol. 128, No. 5-6, 2007, pp. 378-382. http://dx.doi.org/10.1016/j.mad.2007.04.002
[20]	S. Winkler, J. Hagenah, S. Lincoln, M. Heckman, K. Haugarvoll, K. Lohmann-Hedrich, V. Kostic, M. Farrer and C. Klein, “Alpha-Synuclein and Parkinson Disease Susceptibility,” Neurology, Vol. 69, No. 18, 2007, pp. 1745-1750. http://dx.doi.org/10.1212/01.wnl.0000275524.15125.f4
[21]	P. Pals, S. Lincoln, J. Manning, M. Heckman, L. Skipper, M. Hulihan, M. Van den Broeck, T. De Pooter, P. Cras, J. Crook, C. Van Broeckhoven and M. J. Farrer, “Alpha-Synuclein Promoter Confers Susceptibility to Parkinson’s Disease,” Annals of Neurology, Vol. 56, No. 4, 2004, pp. 591-595.http://dx.doi.org/10.1002/ana.20268
[22]	L. Brighina, R. Frigerio, N. K. Schneider, T. G. Lesnick, M. de Andrade, J. M. Cunningham, M. J. Farrer, S. J. Lincoln, H. Checkoway, W. A. Rocca and D. M. Maraganore, “Alpha-Synuclein, Pesticides, and Parkinson Disease: A Case-Control Study,” Neurology, Vol. 70, No. 16 Pt 2, 2008, pp. 1461-1469. http://dx.doi.org/10.1212/01.wnl.0000304049.31377.f2
[23]	B. S. Fahn, R. Elton and M. O. T. U. D. Committee, “Unified Parkinson’s Disease Rating Scale,” Recent Developments in Parkinson’s Disease, Macmillan Health Care Information, Florham Park, 1987, pp. 153-164.
[24]	C. G. Goetz, W. Poewe, O. Rascol, C. Sampaio, G. T. Stebbins, C. Counsell, N. Giladi, R. G. Holloway, C. G. Moore, G. K. Wenning, M. D. Yahr and L. Seidl, “Movement Disorder Society Task Force Report on the Hoehn and Yahr Staging Scale: Status and Recommendations,” Movement Disorders, Vol. 19, No. 9, 2004, pp. 1020-1028. http://dx.doi.org/10.1002/mds.20213
[25]	A. J. Hughes, S. E. Daniel, L. Kilford and A. J. Lees, “Accuracy of Clinical Diagnosis of Idiopathic Parkinson’s Disease: A Clinico-Pathological Study of 100 Cases,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 55, No. 3, 1992, pp. 181-184. http://dx.doi.org/10.1136/jnnp.55.3.181
[26]	Applied Biosystems, “User Bulletin No 2: Abi Prism 7700 Sequence Detection System,” 2001.
[27]	S. Rodriguez, T. R. Gaunt and I. N. M. Day, “Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies,” In: Editor, Eds., Book Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies, publishing house, city, 2009, pp. .
[28]	T. L. Edwards, W. K. Scott, C. Almonte, A. Burt, E. H. Powell, G. W. Beecham, L. Wang, S. Zuchner, I. Konidari, G. Wang, C. Singer, F. Nahab, B. Scott, J. M. Stajich, M. Pericak-Vance, J. Haines, J. M. Vance and E. R. Martin, “Genome-Wide Association Study Confirms SNPs in SNCA and the Mapt Region as Common Risk Factors for Parkinson Disease,” Annals of Human Genetics, Vol. 74, No. 2, 2010, pp. 97-109. http://dx.doi.org/10.1111/j.1469-1809.2009.00560.x
[29]	J. Simon-Sanchez, J. J. van Hilten, B. van de Warrenburg, B. Post, H. W. Berendse, S. Arepalli, D. G. Hernandez, R. M. de Bie, D. Velseboer, H. Scheffer, B. Bloem, K. D. van Dijk, F. Rivadeneira, A. Hofman, A. G. Uitterlinden, P. Rizzu, Z. Bochdanovits, A. B. Singleton and P. Heutink, “Genome-Wide Association Study Confirms Extant Pd Risk Loci among the Dutch,” European Journal of Human Genetics, Vol. 19, No. 6, 2011, pp. 655-661. http://dx.doi.org/10.1038/ejhg.2010.254
[30]	J. Simon-Sanchez, C. Paisan-Ruiz, J. Bras, S. Scholz, R. Gibbs, T. Gasser and A. B. Singleton, “Genome-Wide Analysis in Parkinson’s Disease,” Proceedings European Human Genetics Conference, Vol. 17, Suppl. 2, Vienna, Austria, May 2009, p. 39.
[31]	J. Simón-Sánchez, C. Schulte, J. M. Bras, M. Sharma, J. R. Gibbs, D. Berg, C. Paisan-Ruiz, P. Lichtner, S. W. Scholz, D. G. Hernandez, R. Krüger, M. Federoff, C. Klein, A. Goate, J. Perlmutter, M. Bonin, M. A. Nalls, T. Illig, C. Gieger, H. Houlden, M. Steffens, M. S. Okun, B. A. Racette, M. R. Cookson, K. D. Foote, H. H. Fernandez, B. J. Traynor, S. Schreiber, S. Arepalli, R. Zonozi, K. Gwinn, M. V. D. Brug, G. Lopez, S. J. Chanock, A. Schatzkin, Y. Park, A. Hollenbeck, J. Gao, X. Huang, N. W. Wood, D. Lorenz, G. Deuschl, H. Chen, O. Riess, J. A. Hardy, A. B. Singleton and T. Gasser, “Genome-Wide Association Study Reveals Genetic Risk Underlying Parkinson’s Disease,” Nature Genetics, Vol. 41, No. 12, 2009, pp. 1308-1314. http://dx.doi.org/10.1038/ng.487
[32]	I. Mizuta, W. Satake, Y. Nakabayashi, C. Ito, S. Suzuki, Y. Momose, Y. Nagai, A. Oka, H. Inoko, J. Fukae, Y. Saito, M. Sawabe, S. Murayama, M. Yamamoto, N. Hattori, M. Murata and T. Toda, “Multiple Candidate Gene Analysis Identifies Alpha-Synuclein as a Susceptibility Gene for Sporadic Parkinson’s Disease,” Human Molecular Genetics, Vol. 15, No. 7, 2006, pp. 1151-1158. http://dx.doi.org/10.1093/hmg/ddl030
[33]	J. C. Mueller, J. Fuchs, A. Hofer, A. Zimprich, P. Lichtner, T. Illig, D. Berg, U. Wullner, T. Meitinger and T. Gasser, “Multiple Regions of Alpha-Synuclein Are Associated with Parkinson’s Disease,” Annals of Neurology, Vol. 57, No. 4, 2005, pp. 535-541. http://dx.doi.org/10.1002/ana.20438